###begin article-title 0
Association of Vitamin D Receptor Gene Polymorphism and Parkinson's Disease in Koreans
###end article-title 0
###begin p 1
###xml 28 29 24 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 39 40 35 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 41 42 37 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 190 191 186 187 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 192 193 188 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 412 415 408 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm</italic>
###xml 632 635 628 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm</italic>
###xml 726 727 722 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</italic>
###xml 752 753 748 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 776 778 772 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bb</italic>
###xml 796 797 792 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 295 303 <span type="species:ncbi:9606">patients</span>
###xml 483 491 <span type="species:ncbi:9606">patients</span>
###xml 825 833 <span type="species:ncbi:9606">patients</span>
1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), which is the biologically active form of vitamin D, has anti-inflammatory effects and can prevent experimental Parkinson's disease (PD). 1,25(OH)2D3 exerts most of its actions only after it binds to its specific nuclear receptors. Eighty-five Korean patients with PD and 231 unrelated healthy individuals were evaluated to determine if vitamin D receptor gene (VDRG) BsmI polymorphisms were markers for the susceptibility to PD in Korean patients. Each polymorphism was detected using polymerase chain reaction (PCR)-based restriction analysis. In addition, the relationship between the BsmI polymorphisms and the clinical manifestations of PD was evaluated. Overexpression of the b allele (91.2 vs. 85.7%; p=0.069) and homozygote bb (84.7 vs. 72.7%; p=0.043) was found in the PD patients compared with the controls. These results show for the first time an association between PD and a VDRG polymorphism, which might be involved in the pathogenesis of PD, or in the linkage disequilibrium of the VDRG to another pathogenic gene locus.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 135 136 135 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 201 202 197 198 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 212 213 208 209 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 214 215 210 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 305 306 301 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 317 318 313 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 319 320 315 316 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 426 427 422 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 299 303 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 420 424 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
The glial cell line-derived neurotrophic factor (GDNF) has been suggested to be a candidate treatment for Parkinson's disease (PD) (1, 2). Recent in vivo data suggests that 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) treatment might enhance GDNF mRNA and protein expression in the striatum of adult rats (3). 1,25(OH)2D3 has also been shown to attenuate the hypokinesia and neurotoxicity induced by 6-hydroxydopamine in rats (4).
###end p 3
###begin p 4
###xml 85 86 85 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 334 335 334 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 336 337 336 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 482 483 482 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 622 623 622 623 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 624 625 624 625 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 627 629 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 344 349 <span type="species:ncbi:9606">human</span>
The genomic mechanism of vitamin D is mediated through the vitamin D receptor (VDR) (5). Since the presence of the vitamin D specific nuclear binding in the brain and spinal cord was reported, there has been accumulated evidence suggesting that both the mRNA encoding the VDR and the protein itself are present in the nervous system (6-8). The human VDR gene contains eight coding exons and three alternative 5'non-coding exons spanning more than 75 kb of the DNA on chromosome 12 (9). The VDR belongs to the nuclear hormone receptor superfamily, and modulates the transcription of the target genes in response to 1,25(OH)2D3 (10).
###end p 4
###begin p 5
###xml 70 71 70 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 72 73 72 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
Although several animal studies indicate the potential use of 1,25(OH)2D3 in neurodegenerative diseases, the role of VDR in neurodegeneration has not been clarified and the association between VDR polymorphisms and these diseases has received little attention.
###end p 5
###begin p 6
###xml 254 257 254 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm</italic>
The effect of the VDR genotypes on PD along with their possible importance in predisposing certain individuals to PD prompted us to evaluate the association between the VDR genotype and PD. This study examined the polymorphisms of the VDR gene intron 8 (BsmI) in order to understand the role of the VDR gene in the susceptibility to PD in Koreans. The possible interactions of the VDR gene in terms of gender, the age at onset, clinical expression, and dopa-responsiveness were also investigated.
###end p 6
###begin title 7
MATERIALS AND METHODS
###end title 7
###begin p 8
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 28 31 <span type="species:ncbi:9606">men</span>
###xml 39 44 <span type="species:ncbi:9606">women</span>
###xml 182 190 <span type="species:ncbi:405018">cardinal</span>
###xml 454 462 <span type="species:ncbi:9606">patients</span>
###xml 491 499 <span type="species:ncbi:9606">patients</span>
Eighty-five PD patients (30 men and 55 women, mean age: 64.55+/-8.86 yr) were evaluated by a neurologist and diagnosed with idiopathic PD based on the presence of two or more of the cardinal features of PD (tremor, rigidity, and bradykinesia), as well as by the lack of signs not related to PD. The secondary forms of parkinsonism were excluded. However, no neuropathological investigations were carried out to define the Lewy body pathology because the patients are still alive. All the PD patients included in this study were sporadic based on pedigree analysis. The local ethics committee approved this study, and all the subjects provided informed consent.
###end p 8
###begin p 9
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 751 753 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 232 240 <span type="species:ncbi:9606">patients</span>
###xml 806 814 <span type="species:ncbi:9606">patients</span>
###xml 892 900 <span type="species:ncbi:9606">patients</span>
The age at onset was categorized into early-onset (<50 yr) or late-onset (>70 yr), respectively (11). In order to determine the levodopa-responsiveness, the levodopa test was performed in the morning during a fasting state. All the patients were first rated using the unified Parkinson's disease rating scale (UPDRS) motor subscale, then challenged with a single dose of 250/25 levodopa/carbidopa and re-rated 1 hr later. The dopa-responsiveness was defined as a minimum 30% improvement in the scores (12). The UPDRS was also used to assess the severity of the motor symptoms and signs. An average global tremor score as well as the mean score for the complex of postural instability and gait difficulty (PIGD) was calculated as previously described (13). The tremor-predominant group was defined as those patients with a mean tremor score/mean PIGD score >/=1.5. The PIGD group included all patients with a ratio </=1.0.
###end p 9
###begin p 10
###xml 341 349 <span type="species:ncbi:9606">patients</span>
The control group consisted of 231 unrelated individuals, who were mainly recruited from the health examination clinic of the Kangnam St. Mary Hospital. The control subjects were screened to ensure that there was no history of neurological and psychiatric disorders. The control individuals had an age and gender distribution similar to the patients.
###end p 10
###begin p 11
###xml 319 322 315 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm</italic>
###xml 356 359 352 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm</italic>
###xml 414 415 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 443 446 439 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm</italic>
###xml 606 609 602 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm</italic>
###xml 712 713 708 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</italic>
###xml 848 850 844 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bb</italic>
###xml 934 935 930 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</italic>
The genomic DNA was extracted from the peripheral blood using a Genomic DNA isolation reagent kit (QIAamp(R) kit, Pel-Freez(R) Clinical Systems). The polymerase chain reaction (PCR) for the intron 8 polymorphisms was performed using a PCR thermocycler (ThermoHybaid PCR Sprint, Thermo Electron Corporation, U.S.A.) and BsmI restriction enzyme (Roche). The BsmI VDR polymorphism was tested as described previously (9). The primers flanking the BsmI restriction site are as follows: forward primer, 5'-CAA CCA AGA CTA CAA GTA CCG CGT CAG TGA-3' and backward primer, 5'-AAC CAG CGG GAA GAG GTC AAG GG-3'. The BsmI restriction polymorphism revealed two possible alleles, allele B (absence of a restriction site) and b (presence of a restriction site). The genotypes were defined as BB (absence of restriction site on both alleles, one band at 825 bp), bb (presence of a restriction site on both alleles, two bands at 650 and 175 bp), or Bb (heterozygous, three bands at 825, 650, and 175 bp).
###end p 11
###begin p 12
###xml 490 491 490 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
The allelic and genotypic distributions of the patients and controls were compared. In addition, the following comparisons were performed: the allelic distribution between the early-onset group and the late-onset group, the tremor group and PIGD group, the dopa-responsive group and dopa-non-responsive group. The results were compared using a chi-square test for statistical significance. Calculations were performed using SPSS for Windows version 11.0 (SPSS Inc., Chicago, IL, U.S.A.). A p value <0.05 was considered significant.
###end p 12
###begin title 13
RESULTS
###end title 13
###begin p 14
###xml 95 102 95 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 105 112 105 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 217 218 217 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</italic>
###xml 239 241 239 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bb</italic>
###xml 324 325 324 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</italic>
###xml 343 345 343 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bb</italic>
###xml 388 390 388 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bb</italic>
###xml 583 584 583 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</italic>
###xml 698 699 698 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</italic>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 137 145 <span type="species:ncbi:9606">patients</span>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
###xml 431 439 <span type="species:ncbi:9606">patients</span>
###xml 502 510 <span type="species:ncbi:9606">patients</span>
The gender distribution and the mean age of the PD patients and control subjects were similar (Table 1). Table 2 shows that among the PD patients, two patients (2.4%) had the VDR genotype BB, 11 patients (12.9%) had Bb, and 72 (84.7%) had bb. Among the 231 control subjects, the VDR genotype BB was identified in 3 (1.3%), Bb in 60 (26%), and bb in 168 subjects (72.7%). The VDR genotype bb was significantly more common in the PD patients than in the control subjects. The allelic frequency in the PD patients was 15 (8.8%) with the homozygote B and 155 (91.2%) with the homozygote b, whereas the distribution for the control group was 66 (14.3%) with the homozygote B and 396 with the homozygote b (85.7%).
###end p 14
###begin p 15
###xml 27 29 27 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bb</italic>
###xml 153 160 153 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
###xml 278 280 278 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bb</italic>
###xml 304 311 304 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">Table 4</xref>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 242 249 <span type="species:ncbi:9606">patient</span>
Among the 85 patients, the bb genotype was overexpressed in the PIGD predominant PD patients (94.3%) than in the tremor predominant PD patients (75.6%) (Table 3). The male to female ratio, the age at onset, and the dopa-responsiveness of the patient groups with and without the bb genotype were similar (Table 4).
###end p 15
###begin title 16
DISCUSSION
###end title 16
###begin p 17
###xml 254 257 254 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm</italic>
###xml 260 263 260 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Apa</italic>
###xml 270 273 270 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Taq</italic>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 595 596 595 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 872 874 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 876 878 876 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
Most efforts to identify the sequence variations in the VDR gene have focused on the 3' regulatory region because it is close to the anonymous markers used mainly in association studies. Three adjacent restriction fragment length polymorphism (RFLP) for BsmI, ApaI, and TaqI, which are located near the 3' end of the gene, is known to be involved in regulating expression, particularly through the control of mRNA stability (14). Recent studies have suggested a differential luciferase activity for the two 3' UTR-variants, which are linked to the two most frequent haplotypes, "baT" and "BAt" (9), and a tendency for the BAt haplotype to display somewhat higher of mRNA expression levels than baT (15). At another level, the result by analyzing the in vivo responses to treatment demonstrated a trend for the BAt haplotype to display a somewhat better response than baT (16, 17). Although the influences of this linkage disequilibrium on the VDR protein function and signaling is largely unknown, it is tempting to speculate that individuals with the BAt haplotype have higher numbers of VDR in the target cells, which confer these target cells a better response to vitamin D.
###end p 17
###begin p 18
###xml 44 47 44 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm</italic>
###xml 245 247 245 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bb</italic>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
In view of what has been discussed above, a BsmI polymorphism in intron 8 of the VDR gene can be an intriguing candidate for PD. This study is the first to show an association between the VDR gene polymorphisms and PD. This study found that the bb genotype was more common in those PIGD predominant PD patients compared with the tremor predominant PD patients and the controls.
###end p 18
###begin p 19
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 585 588 585 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm</italic>
It was suggested that PD is not a homogenous entity, but is divisible into two subtypes (a tremor predominant group and a PIGD-predominant group) according to the clinical features as assessed by the components of the UPDRS (18). The PIGD-dominant group had poorer responsiveness to dopaminergic replacement therapy, a rapid progression of motor disabilities and a poor prognosis compared to the tremor-dominant group (13, 18). Therefore, it is possible that different neuronal mechanisms are involved in the development of the major symptoms in PD. In this study, the distribution of BsmI polymorphisms in the tremor predominant group was similar to the control group, whereas in the PIGD-dominant group did not. Although the functional significance of the VDR gene in PIGD predominant PD is still unclear, this study indicates a possible role for the VDR gene in the development of nigrostriatal neuronal loss leading to specific parkinsonian symptoms.
###end p 19
###begin p 20
###xml 131 134 131 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm</italic>
###xml 251 252 251 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</italic>
###xml 258 260 258 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bb</italic>
###xml 320 321 320 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</italic>
###xml 329 331 329 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bb</italic>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 410 411 410 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</italic>
###xml 426 428 426 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bb</italic>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 524 526 524 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bb</italic>
###xml 548 551 548 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm</italic>
###xml 621 623 621 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bb</italic>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 725 727 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
However, care should be taken when interpreting the results of this study because the distribution of the VDR genotype at intron 8 BsmI shows ethnic variations. In this study, the distribution of the VDR genotype in healthy Korean subjects (BB 1.3%, Bb 26%, bb 72.7%) was similar to that in Japanese subjects (BB 3.2%, Bb 25.3%, bb 71.6%) (19). In contrast, Morrison et al. reported the BB genotype in 18.4%, Bb in 52.9%, and bb in 28.7% of healthy controls with Caucasian British-Australian ancestry (20). Suppose that the bb homozygosity for the BsmI genotype is a genetic risk factor for PD, the high frequency of the bb genotype observed in this study may be some contradiction to the lower incidence of PD in Asians (21,22).
###end p 20
###begin p 21
###xml 484 487 484 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm</italic>
###xml 566 569 566 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Apa</italic>
###xml 572 575 572 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Taq</italic>
###xml 581 584 581 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fok</italic>
It should be noted that no firm pathophysiological conclusions could be drawn from this genetic association study. A possible explanation is that the VDR gene polymorphism is a marker of the linkage disequilibrium with another gene, which is actually responsible for the observed association. Furthermore, generalizing these results might be limited because this study population is small. Since the evidence for an association between PD and the VDR gene polymorphisms is based on a BsmI RFLP alone, the distribution of other polymorphisms in the VDR gene, such as ApaI, TaqI and FokI, will need to be analyzed in order to confirm these results. In addition, the role of a VDR gene polymorphism should be further examined in other populations in order to confirm another susceptibility gene for PD and to determine more adequate strategies for treating PD.
###end p 21
###begin article-title 22
Neuroprotective and neurorestorative properties of GDNF
###end article-title 22
###begin article-title 23
Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease
###end article-title 23
###begin article-title 24
###xml 88 92 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
1,25-Dihydroxyvitamin D(3) increases striatal GDNF mRNA and protein expression in adult rats
###end article-title 24
###begin article-title 25
###xml 9 10 9 10 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 65 69 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Vitamin D3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats
###end article-title 25
###begin article-title 26
Vitamin D and regulation of gene expression
###end article-title 26
###begin article-title 27
Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid
###end article-title 27
###begin article-title 28
Brain target sites for 1,25-dihydroxyvitamin D3
###end article-title 28
###begin article-title 29
1,25(OH)2 vitamin D3 sites of action in spinal cord and sensory ganglion
###end article-title 29
###begin article-title 30
Prediction of bone density from vitamin D receptor alleles
###end article-title 30
###begin article-title 31
The RXR heterodimers and orphan receptors
###end article-title 31
###begin article-title 32
Paralysis agitans of early onset with marked diurnal fluctuation of symptoms
###end article-title 32
###begin article-title 33
Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis
###end article-title 33
###begin article-title 34
Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort
###end article-title 34
###begin article-title 35
Diversity of cytoplasmic functions for the 3' untranslated region of eukaryotic transcripts
###end article-title 35
###begin article-title 36
Genetics and biology of vitamin D receptor polymorphisms
###end article-title 36
###begin article-title 37
Vitamin D receptor alleles and rates of bone loss: influences of years since menopause and calcium intake
###end article-title 37
###begin article-title 38
The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype
###end article-title 38
###begin article-title 39
The heterogeneity of Parkinson's disease: Clinical and prognostic implications
###end article-title 39
###begin article-title 40
Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese
###end article-title 40
###begin article-title 41
Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphism and circulating osteocalcin
###end article-title 41
###begin article-title 42
Epidemiology of Parkinson's disease: interplaying gene and environmental factors
###end article-title 42
###begin article-title 43
Prevalence of Parkinson's disease in the biracial population of Copiah county, Mississippi
###end article-title 43
###begin p 44
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of the Parkinson's disease patients and healthy control subjects
###end p 44
###begin p 45
PD, Parkinson's disease; UPDRS, Unified Parkinson's disease rating scale; H & Y, Hoehn & Yahr.
###end p 45
###begin p 46
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Distribution of the VDR genotyping in the Parkinson's disease patients and healthy control subjects
###end p 46
###begin p 47
###xml 81 82 81 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 85 86 83 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 100 106 98 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 109 110 100 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
The values represent the number of patients with the percentages in parenthesis. *chi2=6.308, df=2, daggerchi2=3.318, df=1.
###end p 47
###begin p 48
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Relationship between the VDR genotyping and the clinical signs and findings in the PD patients
###end p 48
###begin p 49
###xml 129 130 129 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 133 134 131 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 148 154 146 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 157 158 148 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
The values represent the number of patients with the percentages in parenthesis. PIGD, postural instability and gait difficulty. *chi2=6.226, df=2, daggerchi2=3.794, df=1.
###end p 49
###begin p 50
###xml 103 111 <span type="species:ncbi:9606">patients</span>
Relationship between VDR genotyping and the age at onset, gender and levodopa-responsiveness in the PD patients
###end p 50
###begin p 51
###xml 81 82 81 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 85 86 83 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 100 106 98 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 109 110 100 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 124 137 115 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8225;</sup>
###xml 140 141 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
The values represent the number of patients with the percentages in parenthesis. *chi2=2.083, df=4, daggerchi2=0.205, df=2, double daggerchi2=7.209, df=2.
###end p 51

